Malarial Vaccines Utilizing Antigen/Adjuvant Display on Viral-Like Particles
Small Business Information
Agave BioSystems, Inc.
P.O. Box 100, Ithaca, NY, 14850
AbstractDevelopment of an effective malarial vaccine has been slow, although recent success in vaccine development has been achieved by using the Plasmodium falciparum circumsporozoite surface protein (CSP)-hepatitis B surface antigen fusions, in conjunction with hepatitis B particles (the RTS, S formulation). The results of these studies suggest the potential of improved malarial vaccines by use of the viral-like particle (VLP)-linked immunogen approach. The VLP technology is being utilized for the development of vaccines for a variety of diseases. Agave BioSystems proposes to develop a novel platform for development of malarial vaccines consisting of a VLP displayed malarial antigen/adjuvant based on the Norwalk virus (NV) capsid protein. The NV-VLP will be engineered to express a candidate antigen in combination with a peptide adjuvant. These VLPs will be characterized, purified and delivered for testing of efficacy to stimulate cellular and humoral immune responses.
* information listed above is at the time of submission.